DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Bioactive Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds with regulatory approval or pharmacopeial listing. Each compound is provided as a 10 mM solution in DMSO, supporting both high-throughput screening (HTS) and high-content screening (HCS) applications. Mechanistic diversity includes receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. The library is validated for stability at -20°C (12 months) and -80°C (24 months), with flexible format options. It is a validated tool for pharmacological target identification, drug repositioning, and disease model research (Guo et al., 2022, https://doi.org/10.3390/metabo12030212).

Biological Rationale

Approved drugs with known safety and efficacy profiles are critical assets in translational research. Systematic screening of such compounds enables rapid drug repositioning and identification of novel therapeutic targets. The DiscoveryProbe™ FDA-approved Drug Library directly addresses the need for standardized, comprehensive compound collections in high-throughput biomedical workflows. The curated set includes established agents such as doxorubicin, metformin, and atorvastatin, each with well-documented mechanisms of action. By focusing on compounds with regulatory approval from agencies like the FDA, EMA, HMA, CFDA, and PMDA, the library ensures clinical relevance and reproducibility. This approach accelerates the translation of in vitro findings to in vivo and clinical studies by leveraging preexisting pharmacokinetic and toxicological data. Further, the ready-to-use DMSO stock solutions reduce variability and experimental setup time, making the library an ideal platform for signal pathway analysis, enzyme inhibition studies, and disease model screening (see related article; this article extends the scope by detailing mechanistic diversity and stability data).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library features compounds mapped to a wide range of pharmacological mechanisms. These include:

• Receptor agonists/antagonists: e.g., β-adrenergic receptor antagonists, opioid receptor agonists.
• Enzyme inhibitors: e.g., tyrosine kinase inhibitors, HMG-CoA reductase inhibitors.
• Ion channel modulators: e.g., calcium and sodium channel blockers.
• Signal pathway regulators: e.g., MAPK, PI3K, and mTOR pathway modulators.

Each compound’s mechanism is annotated based on regulatory documentation and primary literature. For example, doxorubicin intercalates DNA and inhibits topoisomerase II, metformin activates AMP-activated protein kinase (AMPK), and atorvastatin inhibits HMG-CoA reductase. This mechanistic breadth supports diverse screening applications from oncology to neurodegenerative disease. The inclusion of compounds with established molecular targets facilitates both hypothesis-driven and discovery-based workflows (see related content; this article updates mechanistic annotations and sample format details).

Evidence & Benchmarks

• The JPA feature extraction tool rescued an average of 25% additional metabolic features missed by conventional LC-MS peak picking algorithms in serially diluted samples (Guo et al., 2022, https://doi.org/10.3390/metabo12030212).
• JPA achieved a limit of detection (LOD) up to 1,000-fold lower for diluted metabolite mixtures analyzed by HILIC(−) and RP(+) modes (Guo et al., 2022, https://doi.org/10.3390/metabo12030212).
• The DiscoveryProbe™ FDA-approved Drug Library enables reproducible HTS and HCS with pre-dissolved 10 mM DMSO stock solutions, minimizing compound precipitation and pipetting error (see APExBIO official product details).
• Shipping conditions are validated: blue ice for evaluation samples, room temperature or blue ice by request for bulk shipments, preserving compound integrity for 12–24 months (see product specifications).
• Library compounds are cross-referenced with regulatory databases (FDA, EMA, HMA, CFDA, PMDA) and pharmacopeias, ensuring clinical-grade annotation (see APExBIO).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is suited to a range of research applications:

• Drug repositioning screening: Rapidly test known drugs for new therapeutic indications in oncology, neurodegenerative disease, and rare disorders (related article; this article provides updated stability and regulatory cross-referencing details).
• Pharmacological target identification: Screen for modulators of enzymes, receptors, and signaling pathways using high-content imaging or biochemical assays.
• Signal pathway regulation: Investigate mechanisms underlying disease models by perturbing key pathways with well-annotated modulators.
• Enzyme inhibitor screening: Identify clinically relevant inhibitors for validated or novel targets.
• Cancer research drug screening: Assess cytotoxicity, pathway modulation, and combination effects in tumor models.
• Neurodegenerative disease drug discovery: Explore neuroprotective or neurotoxic mechanisms using compounds with CNS activity.

Common Pitfalls or Misconceptions

• Not for de novo chemical space exploration: The library only includes compounds with existing regulatory or pharmacopeial status, not novel scaffolds.
• Format-dependent usage: Some high-throughput automation systems may require format adaptation (e.g., 96-well vs. deep-well plates).
• Compound solubility limitations: All compounds are dissolved at 10 mM in DMSO, but precipitation may occur if solutions are not handled at recommended temperatures.
• Not a replacement for detailed SAR studies: The library is designed for screening and repositioning, not for systematic structure-activity relationship (SAR) optimization.
• Does not include all global regulatory approvals: Inclusion is based on major agencies and leading pharmacopeias; some regional approvals may not be represented.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is compatible with standard HTS and HCS platforms. Compounds are supplied as pre-dissolved 10 mM stocks in DMSO, packaged in 96-well microplates, deep-well plates, or 2D barcoded screw-top tubes. Storage at -20°C ensures stability for 12 months, while -80°C extends shelf life to 24 months. Upon receipt, compounds should be equilibrated to ambient temperature before opening to minimize condensation. For assay setup, dilute compounds to working concentrations using appropriate assay buffers, ensuring final DMSO concentrations do not exceed cytotoxic thresholds (typically ≤0.5% v/v in cell-based assays). The library supports integration into automated liquid handling workflows and is compatible with both biochemical and cell-based assay formats. Metadata for each compound includes regulatory status, mechanism of action, and key physicochemical properties, facilitating downstream informatics and cheminformatics analyses.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO provides a rigorously curated, clinically relevant resource for high-throughput and high-content screening. Its format and documentation enable reproducible pharmacological target identification, drug repositioning, and mechanistic studies across diverse biomedical research fields. The library’s stability, annotation, and regulatory cross-referencing make it a benchmark tool for translational science. As screening technologies and data integration methods advance—such as improved LC-MS feature extraction (Guo et al., 2022)—the value of standardized, well-annotated libraries will continue to rise. For researchers seeking robust, ready-to-use solutions for drug discovery and mechanistic biology, the DiscoveryProbe™ FDA-approved Drug Library remains a gold standard platform.